RXST · RxSight, Inc.
Market Cap
$250.39M
Shares
41.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.02
Open$6.00
Day$5.78–6.03
52W close$4.59–13.09
Avg vol 30d846K
Short int3.9M · 9.3% float · 4.6d
Short vol56%
Last earningsJul 6, 2026
DataJul 2021–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Oct 5, 2026
Est · unconfirmed
· in 3 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$127.58M
Trailing 12 months
Net income (TTM)
−$46.95M
Trailing 12 months
Revenue growth YoY
+0.3%
Year over year
Operating margin
-43.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.8%
Year over year · more shares
Price change (1Y)
-36.1%
Trailing year
Short interest
9.3%
Latest settlement · 4.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−1%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−7%
trailing
YTD return
−42%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$118.0K over 90 days · 100% sells
Short interest
Falling
9.32% of float · ▼ -9.0% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
151 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
Gross margin
77%
expanding
EPS growth
−34%
Y/Y
Free cash flow
$-19.3M
Balance sheet
$9.7M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 5, 2026
2026 full year revenue
· 2026 full year
Initiated
$140M – $160M
prior FY $134.48M
midpoint +11.5% Y/Y
Full-year gross margin
· 2026 full year
Initiated
73% – 75%
Operating expenses
· 2026 full year
Initiated
$150M – $160M
Prior guidance
period ended
· from the 8-K filed Aug 5, 2024
Revenue
· 2024 full-year
$139M – $140M
Operating expenses
· 2024 full-year
$135M – $136M
Gross margin
· 2024 full-year
68% – 70%
Guided vs delivered
· last 1 settled
Revenue
2024 full-year
guided $139M – $140M
$139.93M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$118.0K over 90 days · 100% sells
Short interest
Falling
9.32% of float · ▼ -9.0% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
151 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $6 · 17%
Range high $13
vs 200-day avg -20%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RXST
this stock
RxSight, Inc.
|
$250.39M | -42.2% | -3.9% | — | 9.3% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RXST | -8.0% | -14.1% | -6.5% | -17.9% | -42.2% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -6.8% | -12.4% | -24.4% | -17.5% | -54.3% |
Key facts
CIK
1111485
CUSIP
78349D107
13F (30d)
60 filings
60 filers
Visit website
Investor relations